Why was cisapride withdrawn from the US market?

Prepare for the ASPEN Certified Nutrition Support Clinician (CNSC) Exam. Study with structured quizzes and detailed insights to enhance your knowledge and readiness. Get set for success!

Multiple Choice

Why was cisapride withdrawn from the US market?

Explanation:
Drug-induced QT prolongation leading to potentially fatal ventricular arrhythmias explains why cisapride was withdrawn. Cisapride is a prokinetic that can affect cardiac repolarization by prolonging the QT interval, increasing the risk of torsades de pointes. This risk is higher when cisapride levels are increased by drug interactions (notably CYP3A4 inhibitors) or by electrolyte disturbances. As reports of serious cardiac events grew, the FDA removed cisapride from the U.S. market to prevent further harm. The other listed adverse effects (constipation, liver failure, pancreatitis) were not the driving reason for the withdrawal.

Drug-induced QT prolongation leading to potentially fatal ventricular arrhythmias explains why cisapride was withdrawn. Cisapride is a prokinetic that can affect cardiac repolarization by prolonging the QT interval, increasing the risk of torsades de pointes. This risk is higher when cisapride levels are increased by drug interactions (notably CYP3A4 inhibitors) or by electrolyte disturbances. As reports of serious cardiac events grew, the FDA removed cisapride from the U.S. market to prevent further harm. The other listed adverse effects (constipation, liver failure, pancreatitis) were not the driving reason for the withdrawal.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy